Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University, through its innovation arm Oxford University Innovation (OUI), has entered into an option agreement for a universal influenza vaccine with US-based startup Blue Water Vaccines (BWV), which is raising $15m to support development of the flu shot.

3D rendering of microscopic virus in front of abstract background © Shutterstock

Developed by scientists at the University’s Department of Zoology the vaccine protects against all influenza strains by targeting parts of the virus that induce a protective immune response but are also limited in variability. The technology has the potential of providing life-long immunity against flu.

Influenza is a major respiratory pathogen. It is estimated that there are over almost 500,000 deaths a year caused by influenza, with somewhere between three to five million severe cases of illness annually. The virus is estimated to cost $87.1bn in absenteeism in the US alone. Current influenza vaccines target highly variable epitopes of the virus which evolve and change annually, meaning flu vaccines need to be updated and redistributed every season while only typically providing protection to 50% of the individuals who receive it. Conversely, the universal flu vaccine developed at Oxford University targets epitopes that are both naturally immunogenic and limited in variability, allowing for a vaccine that protects against all influenza strains and avoids the need to be regularly updated.

Read more (University of Oxford website)

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Researchers discover novel form of adaptation in the auditory system

Researchers in the Department of Physiology, Anatomy and Genetics (DPAG) have found that the auditory system adapts to the changing acoustics of reverberant environments by temporally shifting the inhibitory tuning of cortical neurons to remove reverberation.

20 minutes of daily exercise can keep teens' doctors away

Teenagers should exercise vigorously for at least 20 minutes per day to reap increased cardiorespiratory fitness (CRF), according to a cross-sectional study from the UK led by University of Oxford researchers.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.